Table 5.

Prognostic factors in patients with HCC who received sorafenib treatment: uni- and multivariate analyses

Variable	Univariate analysis			Multivariate analysis
	HR	95% CI	p value	HR	95% CI	p value
Age >70 years	0.834–1.699	1.190	0.337
Male gender	1.034	0.815–1.311	0.784
Viral etiology	1.011	0.722–1.300	0.733
Time since first HCC diagnosis >12 months	0.888	0.789–1.000	0.049			0.723
Child-Pugh B status (0 vs. 1)	2.638	1.751–3.972	<0.001	2.093	1.364–3.211	0.0001
Performance status (0 vs. 1)	1.651	1.287–2.118	<0.001	1.357	1.043–1.765	0.023
Macrovascular invasion	1.770	1.373–2.282	<0.001	1.722	1.331–2.622	<0.001
Extrahepatic spread	1.250	0.989–1.584	0.095			0.111
AFP ≥400 ng/mL	1.486	1.147–1.924	0.003	1.328	1.024–1.724	0.033
Dermatological adverse events	0.562	0.436–0.725	<0.001	0.624	0.482–0.808	<0.001
Period of treatment (2013–2017 vs. 2008–2012)	0.694	0.547–0.880	0.003	0.728	0.581–0.937	0.013

AFP, alpha-fetoprotein; HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval. Modified from Ref. [7].